Amy Elazzouzi is President & VP at Aura Biosciences, Inc. (AURA). They have made 8 open-market trades across 1 company since 2024, most recently 2026-09-01.
CIK 0002042910
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AURA | 143,600 | $877K |
Shares reported on the most recent Form 4, priced at the 2026-09-01 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AURA | SELL | 2026-02-17 | 2026-02-17 | $5.06 | $43K | +12.6% | +25.8% | +43.0% |
| AURA | SELL | 2026-01-20 | 2026-01-20 | $4.86 | $8K | +12.7% | +7.8% | +41.9% |
| AURA | SELL | 2025-10-29 | 2025-10-29 | $6.35 | $6K | -9.4% | +8.4% | -7.1% |
| AURA | SELL | 2025-08-18 | 2025-08-18 | $6.70 | $103K | -3.2% | -8.1% | -17.2% |
| AURA | SELL | 2025-04-16 | 2025-04-16 | $5.49 | $5K | +3.5% | +10.8% | +22.2% |
| AURA | SELL | 2025-02-18 | 2025-02-18 | $7.75 | $11K | -3.4% | -4.3% | -23.6% |
| AURA | SELL | 2025-01-21 | 2025-01-21 | $7.67 | $8K | -0.5% | -3.3% | -29.4% |
| AURA | SELL | 2024-10-29 | 2024-10-29 | $10.74 | $6K | +3.6% | -11.3% | -23.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.